Genetic screening for iron overload: No evidence of discrimination at 1 year
- PMID: 17908514
Genetic screening for iron overload: No evidence of discrimination at 1 year
Abstract
Purpose: This study measured the extent of insurance and employment problems associated with population screening for hereditary hemochromatosis and iron overload.
Methods: 101,168 primary care patients from the US and Canada were screened for iron phenotypes and HFE genotypes associated with hemochromatosis. Those identified to be at risk (2253) were offered a clinical examination, which 1677 (74%) accepted, and the 1154 of these who responded to an initial questionnaire about psychosocial issues were surveyed 1 year later about whether they had experienced problems with insurance or employment that they attributed to hereditary hemochromatosis and iron overload.
Results: 832 (72.1%) of the 1154 participants surveyed after 1 year responded to the second survey. Three (0.4%) had verified problems with insurance or employment that they believed were related to hereditary hemochromatosis and iron overload. Two had problems with life insurance, and one with long-term care insurance. All 3 had elevated iron levels but not a relevant HFE genotype. One of the life insurance problems was resolved; the second one was not serious. The participant who was denied long-term care insurance had other health conditions unrelated to hereditary hemochromatosis and iron overload that could have contributed to the denial. No problems were verified for health insurance or employment, or from any of the comparison group participants (controls and those with inconclusive screening results).
Conclusions: The risk of insurance or employment problems 1 year after phenotype and genotype screening for hereditary hemochromatosis and iron overload is very low.
Similar articles
-
Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage.Am J Gastroenterol. 2003 May;98(5):1175-80. doi: 10.1111/j.1572-0241.2003.07405.x. Am J Gastroenterol. 2003. PMID: 12809845
-
Genetic discrimination and screening for hemochromatosis.J Public Health Policy. 1994 Autumn;15(3):345-58. J Public Health Policy. 1994. PMID: 7983195
-
An analysis of the proposal for population based screening for hereditary hemochromatosis in Massachusetts.J Biolaw Bus. 2001;4(4):51-8. J Biolaw Bus. 2001. PMID: 12751496
-
Screening for hemochromatosis: phenotype versus genotype.Semin Hematol. 1998 Jan;35(1):72-6. Semin Hematol. 1998. PMID: 9460810 Review.
-
Clinical aspects of hemochromatosis.Semin Liver Dis. 2005 Nov;25(4):381-91. doi: 10.1055/s-2005-923310. Semin Liver Dis. 2005. PMID: 16315132 Review.
Cited by
-
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.Hepatology. 2011 Jul;54(1):328-43. doi: 10.1002/hep.24330. Hepatology. 2011. PMID: 21452290 Free PMC article. No abstract available.
-
Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation values from 44,809 participants of the HEIRS study.Can J Gastroenterol Hepatol. 2014 Oct;28(9):502-4. doi: 10.1155/2014/698352. Can J Gastroenterol Hepatol. 2014. PMID: 25314357 Free PMC article.
-
Genetic discrimination and life insurance: a systematic review of the evidence.BMC Med. 2013 Jan 31;11:25. doi: 10.1186/1741-7015-11-25. BMC Med. 2013. PMID: 23369270 Free PMC article.
-
The diagnosis and management of hereditary haemochromatosis.Clin Biochem Rev. 2010 Feb;31(1):3-8. Clin Biochem Rev. 2010. PMID: 20179792 Free PMC article.
-
Management of elevated serum ferritin levels.Gastroenterol Hepatol (N Y). 2008 May;4(5):333-4. Gastroenterol Hepatol (N Y). 2008. PMID: 21904507 Free PMC article. No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
